

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) An epidermal growth factor receptor (EGFR)-derived peptide ~~or mutant peptide thereof~~ which is capable of inducing a cytotoxic T lymphocyte and an antibody specific for said peptide, wherein the EGFR-derived peptide consists of at least 8 consecutive amino acid residues derived from the amino acid sequence of EGFR₈₀₀₋₈₀₉ (SEQ ID NO: 1), EGFR₁₂₄₋₁₃₂ (SEQ ID NO: 2), EGFR₅₄₋₆₂ (SEQ ID NO: 3), EGFR₄₇₉₋₄₈₈ (SEQ ID NO: 4) or EGFR₁₁₃₈₋₁₁₄₇ (SEQ ID NO: 5).

2. (Cancelled)

3. (Currently Amended) A polypeptide consisting of 8 to 50 amino acid residues, which comprises the peptide of Claim 1 ~~or 2~~ and is capable of inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

4. (Withdrawn - Currently Amended) A nucleic acid molecule encoding the peptide of Claim 1 ~~or 2~~.

5. (Withdrawn) A vector comprising the nucleic acid molecule of Claim 4.

6. (Currently Amended) A pharmaceutical composition comprising the peptide of Claim 1 ~~or 2~~, for inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

7. (Original) The pharmaceutical composition of Claim 6, which is used as a cancer vaccine.

8. (Withdrawn – Currently Amended) An EGFR-reactive cytotoxic T lymphocyte which recognizes a complex between the peptide of Claim 1 ~~or 2~~ and an HLA molecule.

9. (Withdrawn – Currently Amended) A method for inducing an EGFR-reactive cytotoxic T lymphocyte using the peptide of Claim 1-~~or 2~~.

10. (Withdrawn - Currently amended) An antibody which specifically recognizes the peptide of Claim 1-~~or 2~~.

11. (Withdrawn) A nucleic acid molecule encoding the polypeptide of Claim 3.

12. (Withdrawn) A vector comprising the nucleic acid molecule of Claim 11.

13. (Previously Presented) A pharmaceutical composition comprising the peptide of Claim 3, for inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

14. (Previously Presented) The pharmaceutical composition of Claim 13, which is used as a cancer vaccine.

15. (Withdrawn) A pharmaceutical composition comprising the nucleic acid molecule of Claim 4, for inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

16. (Withdrawn) The pharmaceutical composition of Claim 15, which is used as a cancer vaccine.

17. (Withdrawn) An EGFR-reactive cytotoxic T lymphocyte which recognizes a complex between the polypeptide of Claim 3 and an HLA molecule.

18. (Withdrawn) A method for inducing an EGFR-reactive cytotoxic T lymphocyte using the polypeptide of Claim 3.

19. (Withdrawn) An antibody which specifically recognizes the polypeptide of Claim 3.